Collin J.Kurtenbach

Associate

Chicago + 1.312.269.4086

Connect:

Share

Collin Kurtenbach's litigation practice focuses on representing clients in asserting and defending their intellectual property rights before U.S. district courts and the International Trade Commission (ITC). The majority of his work deals with patent law, but he also has experience with trade secrets. In the patent arena, Collin emphasizes his bioengineering background to assist clients in complex Hatch-Waxman litigation and lawsuits related to various types of medical devices as well as in litigating intellectual property rights relating to semiconductors, smartphones, and biotechnology.

Collin's practice runs the gamut of a typical case. During his career, he has been intimately involved in pre-lawsuit due diligence, drafting of the complaint, coordinating discovery, drafting motions, preparing for and taking depositions of fact and expert witnesses, working with experts, trial, and post-trial briefing. His attention to detail makes him a valuable member of any trial team.

Prior to attending law school, Collin worked in the research and development and in the intellectual property departments of Cardinal Health. During this time he assisted in the design, development, and legal protection of medical devices. He also supported the company in its mergers and acquisition work by validating and onboarding certain intellectual property.

Experience

  • McDonald's obtains dismissal after moving for summary judgment on BIPA claimsJones Day defended McDonald's Corporation against allegations that an artificial intelligence (AI)/machine learning (ML) system for automating orders at a restaurant drive-thru violated the Illinois Biometric Information Privacy Act (BIPA) by capturing Plaintiff's biometric information when he placed his restaurant order.
  • NXP settles global patent dispute with MediaTek over semiconductor technologyJones Day represented NXP Semiconductors N.V. et al. as complainant/plaintiff in a patent infringement dispute against competitor MediaTek Inc. et al. before the International Trade Commission (ITC) and the United States District Court for the Central District of California. 
  • Newell Brands sells The United States Playing Card Company to Cartamundi GroupJones Day advised Newell Brands Inc. in the sale of The United States Playing Card Company ("USPC") to Cartamundi Group, a leading manufacturer and distributor of playing cards and board games.
  • Huawei defends patent litigation relating to smartphone patentsJones Day represented Huawei Device USA Inc. in patent litigation brought by American Patents, LLC in the Eastern District of Texas.
  • Celgene asserts its POMALYST® patents against multiple generic companies under Hatch-Waxman ActJones Day is representing Celgene Corporation as a plaintiff to enforce its patents against multiple pharmaceutical companies including Teva Pharmaceuticals USA, Inc.; Apotex, Inc.; Hetero Labs Limited; Aurobindo Pharma Ltd.; Mylan Pharmaceuticals Inc.; Breckenridge Pharmaceutical, Inc.; and Natco Pharma Limited in several Hatch-Waxman litigation matters involving their proposed generic versions of POMALYST®, which is prescribed for treating multiple myeloma.
  • 3D Systems defends antitrust lawsuit brought by KLS Martin against Medical ModelingJones Day defended a lawsuit brought by KLS Martin, Inc. against Medical Modeling, Inc., a wholly-owned subsidiary of 3D Systems, Inc., for violations of the Florida antitrust act and other laws.
  • Celgene successfully blocks PTAB institution of IPR involving REVLIMID®Jones Day represented Celgene Corporation in successfully blocking institution of inter partes review ("IPR") of a patent covering the use of Celgene's REVLIMID® brand drug to treat multiple myeloma.
  • Celgene successfully blocks institution of inter partes review on three patents listed in the Orange Book for its blockbuster REVLIMID® productJones Day represented Celgene Corporation in successfully blocking institution of inter partes review ("IPR") of three patents covering the use of Celgene's REVLIMID® brand drug to treat myelodysplastic syndrome (“MDS”).
  • UPL acquires Arysta LifeScience from Platform Specialty Products Corporation for $4.2 billionJones Day advised UPL Limited ("UPL"), a leading global generic agrochemical company based in India, in connection with its subsidiary, UPL Corporation Limited’s, US$4.2 billion acquisition and related $3 billion term financing of Arysta Lifescience Inc. (“Arysta”), a global provider of crop protection solutions, including bio-solutions and seed treatment, from NYSE listed Platform Specialty Products Corporation (“Platform”).
  • Newell Brands sells Pure Fishing to Sycamore Partners for $1.3 billionJones Day advised Newell Brands Inc. in the sale of its Pure Fishing business to Sycamore Partners for approximately $1.3 billion in cash.
  • Celgene asserts its REVLIMID® patents against Apotex Inc. under Hatch-Waxman ActJones Day is representing Celgene Corporation as a plaintiff to enforce its patents against Apotex Inc. in a Hatch-Waxman litigation matter involving Apotex’s proposed generic versions of REVLIMID®, which is prescribed for treating multiple myeloma and other cancers.
  • Celgene asserts its REVLIMID® patents against Sun Pharma under Hatch-Waxman ActJones Day is representing Celgene Corporation as a plaintiff to enforce its patents against Sun Pharma Global FZE, Sun Pharma Global Inc., Sun Pharmaceutical Industries, Inc., and Sun Pharmaceutical Industries Limited in a Hatch-Waxman litigation matter involving Sun’s proposed generic versions of REVLIMID®, which is prescribed for treating multiple myeloma and other cancers.
  • Celgene enforces its REVLIMID® patents against Lotus Pharmaceutical under Hatch-Waxman ActJones Day is representing Celgene Corporation as a plaintiff to enforce its patents against Lotus Pharmaceutical Co., Ltd. in Hatch-Waxman litigations involving proposed generic versions of REVLIMID®, which is prescribed for treating multiple myeloma and other cancers.
  • J.F. Lehman sells National Response Corporation and Sprint Energy Services to Hennessy Capital Acquisition Corp. IIIJones Day advised long standing client J.F. Lehman & Company, a leading mid-market private equity firm focused on the defense, aerospace, and maritime sectors, in connection with (i) the sale of all its membership interests in NRC Group Holdings, LLC, formed earlier this year through the combination of JFLCO portfolio companies National Response Corporation and Sprint Energy Services, to Hennessy Capital Acquisition Corp. III, and (ii) the related refinancing of the credit facilities of such portfolio companies.
  • HD Supply completes $750 million offering of Senior NotesJones Day represented HD Supply, Inc., one of the largest industrial distributors in North America, in connection with its issuance of $750 million in aggregate principal amount of 5.375% Senior Notes due 2026 in a Rule 144A and Regulation S offering.
  • Marathon Petroleum acquires Andeavor in deal valued at $23.3 billionJones Day advised Marathon Petroleum Corp. (NYSE: MPC) in connection with the acquisition and related financing of Andeavor (NYSE: ANDV) to create a leading U.S. refining, marketing, and midstream company.
  • Celgene asserts its REVLIMID® patents against Cipla under Hatch-Waxman ActJones Day is representing Celgene Corporation as a plaintiff to enforce its patents against Cipla Limited in Hatch-Waxman litigation matters involving Cipla’s proposed generic versions of REVLIMID®, which is prescribed for treating multiple myeloma and other cancers.
  • Connell Limited Partnership sells Anchor Danly and AWC Manufacturing to Hidden Harbor Capital PartnersJones Day represented Connell Limited Partnership in connection with its sale of Anchor Danly and AWC Manufacturing, manufacturers and distributors of industrial tooling and metal fabrication services to tool and mold companies, to Hidden Harbor Capital Partners.
  • Celgene asserts its REVLIMID® patents against Dr. Reddy’s Laboratories under Hatch-Waxman ActJones Day is representing Celgene Corporation as a plaintiff to enforce its patents against Dr. Reddy's Laboratories in several Hatch-Waxman litigation matters involving DRL's proposed generic versions of REVLIMID®, which is prescribed for treating multiple myeloma and other cancers.
    • View All

    January 2022 Commentary

    Inducement Suit Proceeds Against Insurance Company for Encouraging Use of Generic Drug

    September 2021 Commentary

    Federal Circuit Vacates Judgment, Reinstates Jury's Verdict of Induced Infringement

    April 2019 Alert

    Polymorph Patent Not Invalid as Obvious

    April 2018 Jones Day Publications

    2018 Update: Annotated Local Patent Rules for the Northern District of Illinois

    Before sending, please note:

    Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.